

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2010; month=12; day=1; hr=14; min=55; sec=30; ms=225;]

=====

Application No:	10576440	Version No:	2.0
-----------------	----------	-------------	-----

Input Set:

Output Set:

Started:	2010-11-26 11:59:33.492
Finished:	2010-11-26 11:59:33.594
Elapsed:	0 hr(s) 0 min(s) 0 sec(s) 102 ms
Total Warnings:	0
Total Errors:	0
No. of SeqIDs Defined:	2
Actual SeqID Count:	2

SEQUENCE LISTING

<110> BOUREL, DOMINIQUE
GLACET, ARNAUD
JORIEUX, SYLVIE
STURA, ENRICO
DUCANCEL, FREDERIC
TEILLAUD, JEAN-LUC

<120> USE OF METALLIC CATIONS TO IMPROVE FUNCTIONAL ACTIVITY OF
ANTIBODIES

<130> 096183-0104

<140> 10576440

<141> 2010-11-26

<150> PCT/FR2004/002687

<151> 2004-10-20

<150> FR 0312228

<151> 2003-10-20

<160> 2

<170> PatentIn version 3.5

<210> 1

<211> 1428

<212> DNA

<213> Homo sapiens

<220>

<223> cDNA sequence of double mutant His310-435Lys

<400> 1

atggagtttg ggctgagctg ggttttctc gttgctcttt taagagggtgt ccagtgtcag	60
gtgcagctgg tggagtctgg gggaggcgtg gtccagcctg ggaggteccct gagactctcc	120
tgtacagcct ctggattcac cttcaaaaac tatgctatgc attgggtccg ccaggctcca	180
gccaaggggc tggagtgggt ggcaactata tcatatgatg gaaggaatat acaatatgca	240
gactccgtga agggccgatg caccttctcc agagacaatt ctcaggacac cctgtatctg	300
caactgaaca gcctcagacc ggaggacacg gctgtgtatt actgtgcgag acccgtaaga	360
agccgatggc tgcaattagg tcttgaagat gcttttcata tctggggcca ggggacaatg	420
gtcaccgtct cttcagcctc caccaagggc ccacgggtct tccccctggc accctcctcc	480
aagagcacct ctggggggcac agcggccctg ggctgcctgg tcaaggacta cttccccgaa	540
ccggtgacgg tgtcgtggaa ctcaggcgcc ctgaccagcg gcgtgcacac cttccccggt	600

gtcctacagt cctcaggact ctactccctc agcagcgtgg tgaccgtgcc ctccagcagc 660
ttgggcaccc agacctacat ctgcaacgtg aatcacaagc ccagcaacac caaggtggac 720
aagaaagttg agcccaaate ttgtgacaaa actcacacat gcccacgtg cccagcacct 780
gaactcctgg ggggaccgtc agtcttctc tccccccaa aaccaagga caccctcatg 840
atctcccgga cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag 900
gtcaagttca actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg 960
gaggagcagt acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gaagcaggac 1020
tggtctgaatg gcaaggagta caagtgaag gtctccaaca aagccctccc agccccatc 1080
gagaaaacca tctccaaagc caaagggcag ccccgagaac cacaggtgta caccctgccc 1140
ccatcccggg atgagctgac caagaaccag gtcagcctga cctgcctggc caaaggcttc 1200
tatcccagcg acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag 1260
accacgcctc ccgtgctgga ctccgacggc tccttcttcc tctacagcaa gctcaccgtg 1320
gacaagagca ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg 1380
cacaacaagt acacgcagaa gagcctctcc ctgtctccgg gtaaatag 1428

<210> 2
<211> 475
<212> PRT
<213> Homo sapiens

<220>
<223> Peptide sequence of double mutant His310-H435Lys.

<400> 2
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1 5 10 15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
20 25 30

Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe
35 40 45

Lys Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Ala Lys Gly Leu
50 55 60

Glu Trp Val Ala Thr Ile Ser Tyr Asp Gly Arg Asn Ile Gln Tyr Ala
65 70 75 80

Asp	Ser	Val	Lys	Gly	Arg	Cys	Thr	Phe	Ser	Arg	Asp	Asn	Ser	Gln	Asp
			85					90						95	
Thr	Leu	Tyr	Leu	Gln	Leu	Asn	Ser	Leu	Arg	Pro	Glu	Asp	Thr	Ala	Val
			100					105						110	
Tyr	Tyr	Cys	Ala	Arg	Pro	Val	Arg	Ser	Arg	Trp	Leu	Gln	Leu	Gly	Leu
		115						120				125			
Glu	Asp	Ala	Phe	His	Ile	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser
	130						135				140				
Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser
145					150					155					160
Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp
				165					170						175
Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr
			180						185				190		
Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr
		195						200					205		
Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln
	210					215						220			
Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp
225					230					235					240
Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro
			245						250					255	
Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro
			260					265					270		
Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr
			275				280					285			
Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn
			290				295				300				

Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	
305					310					315					320	
Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	
				325					330					335		
Leu	Lys	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	
			340					345					350			
Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	
		355					360					365				
Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	
	370					375					380					
Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	
385					390					395					400	
Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	
				405					410					415		
Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	
			420					425					430			
Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	
		435					440					445				
Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	Lys	Tyr	
	450					455					460					
Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys						
465					470					475						